MDS-ES the Non-Motor Vital Three of Parkinson’s Disease: Sleep and Fatigue; Dysautonomia; and Pain

MDS-ES the Non-Motor Vital Three of Parkinson’s Disease: Sleep and Fatigue; Dysautonomia; and Pain

 

Please join this three part streaming series starting:

 

  • Thursday, April 8, 2021
    • Sleep and Fatigue: The Known, the Unknown and Key Issues
  • Friday, April 30, 2021
    • Dysautonomia and Clinical Implications in Parkinson’s Disease
  • Friday, May 7, 2021
    • Pain: The hidden crisis in Parkinson’s disease

Register

Course Director

K Ray Chaudhuri, MD, DSc, FRCP, FEAN; King’s College London, London, United Kingdom

Faculty

Angelo Antonini, MD, PhD
Kirsty Bannister, PhD
Claudio L. Bassetti, MD
Cristian Falup-Pecurariu, MD, PhD
Alessandra Fanciulli, MD, PhD
Wassilios Meissner, MD, PhD
Jalesh N. Panicker, MD, FRCP
Olivier Rascol, MD, PhD
Ambra Stefani, MD

Course Description

In this unique course, spanning three separate sessions, we bring you clinical and basic science orientated insights to these disabling and troubling “vital” three NMS of PD illustrated with practical tips and case histories so the learnings can be translated to day to day clinical practice as well as enable locally driven research in relevant areas. The faculty reflects gender balance, new and established speakers as well as geographical diversity while maintaining quality of the science.

Non-motor symptoms (NMS) are now widely recognized as integral to the natural history of Parkinson’s disease (PD), featuring from the prodromal premotor phase to late palliative. While NMS range from cognitive dysfunction to sleep dysfunction, pain, and fatigue, the broader focus has been on dementia and cognitive impairment in PD. Other “vital” aspects of the NMS range have not been thoroughly addressed. Among these “vitals” of NMS of PD are problems and dysfunctions of sleep with wide ranging impact on quality of life, cognition and daytime functioning; fatigue specifically highlighted by the recent COVID-19 pandemic; the many aspects of autonomic dysfunction that may blight day to day activities of a person with Parkinson’s; and pain, the hidden menace of PD in many of its forms, central and peripheral.

Session 1: Sleep and Fatigue: The Known, the Unknown and Key Issues (April 8)
Sleep dysfunction blights the lives of over 90% of people with Parkinson’s disease and is multifactorial while fatigue can be a troublesome yet an insidious non-motor symptom of PD. Both can lead to severely compromised quality of life, may be undeclared in consultations, and as such poorly recognized and treated.

Session 2: Dysautonomia and Clinical Implications in Parkinson’s Disease (April 30)
Autonomic dysfunction can occur in many forms, from cardiovascular to sweating, and can affect brain as well as peripheral nervous systems and viscera. Its impact in PD is poorly recognized and novel treatment strategies need designing.

Session 3: Pain: The hidden crisis in Parkinson’s disease (May 7)
Many regard pain to be a hidden epidemic in PD and chronic pain is highly prevalent in PD and is rated by patients as one of the most bothersome symptom.  Yet recognition, classification, robust biomarkers as well as treatment remains poorly evidence based and suboptimal. This will be discussed in this session.

Interactive Components

Following the lectures, faculty will present illustrated case histories addressing “Lessons Learned From My Patients” and “Challenging Cases”.  Live panel discussion of case histories and moderated question and answer will close each session.

Target Audience

This course is intended for neurologists, movement disorder specialists, fellows, residents, students, researchers and health professionals with an interest in the measurement and management of non-motor symptoms in patients with Parkinson’s disease.

Learning Objectives 
  1. Identify the vital three non-motor symptoms in Parkinson’s disease patients
  2. Develop a management plan for the treatment of the vital three non-motor symptoms in Parkinson’s disease patients
  3. Apply management plan for the treatment of the vital three to clinical practice
  4. Evaluate opportunities to incorporate assessment of non-motor symptoms into clinical care training
  5. Innovate opportunities in practice to enable research to formulate research projects and papers
Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The International Parkinson and Movement Disorder Society designates this activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation.

Satisfactory Completion:

Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.

Content Validity Statement:

All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.

Disclosure of Financial Relationships & Resolution:

All individuals in control of content for this activity are required to disclose all financial relationships with ineligible companies (as defined by the ACCME) over the last 24 months. Disclosure information is available here.


All relevant financial relationships have been mitigated in advance of this program.

EAN

 

This meeting has been endorsed by the European Academy of Neurology.

Course Program


Registration

Register

Participants can register throughout the series and do not need to register for individual sessions; registration is for the entire series.

Registration closes May 8, 2021

Registration Fee:

MDS Member: Free

Non-Member: $50 USD

*Non-Members wishing to apply for MDS Membership to receive the MDS Member rate for this course will need to apply for membership no later than 2 weeks in advance of session.

Currency converter: https://www.xe.com/


Sponsorship


Contact Education

Top

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice